- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.04. | Pila Pharma AB: Update To Preclinical Rat Obesity Studies - Low Exposure Of Xen-d0501 Could Explain Lack Of Effect On Bodyweight | 119 | GlobeNewswire (Europe) | PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company"), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition, today announces that drug exposure in the obese rat studies... ► Artikel lesen | |
| 10.02. | Pila Pharma AB: Pila Pharma today publishes the Company's year-end report for the period January - December 2025. | 212 | GlobeNewswire (Europe) | The report can be found on the Company's website:
https://pilapharma.com/financial-reports/SUMMARY OF YEAR-END REPORT
SECOND HALF YEAR (1 JULY- 31 DECEMBER 2025)
Operating income amounted to... ► Artikel lesen | |
| 26.01. | Pila Pharma AB: Pila Pharma Signs With New Clinical Cro To Prepare For Clinical Phase In Obesity After Preclinical Obesity Studies | 253 | GlobeNewswire (Europe) | Malmö, 26 January 2026
PILA PHARMA AB (publ) (FN STO: PILA) ("PILA PHARMA" or the "Company"), an innovative biotech company developing a novel oral, small molecule TRPV1 inhibitor, today announces that... ► Artikel lesen | |
| 30.09.25 | Pila Pharma AB: Pila Pharma Enters Into Agreement With The Danish preclinical Contract Research Organisation Gubra On Preclinical Trials Of Xen-d0501 In Obesity | 600 | GlobeNewswire (Europe) | PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs for treatment of obesity and diabetes based on TRPV1 inhibition, informs investors and others with interest... ► Artikel lesen | |
| PILA PHARMA Aktie jetzt für 0€ handeln | |||||
| 27.08.25 | Pila Pharma AB: Pila Pharma Publishes Interim Report (1 January - 30 June 2025) | 567 | GlobeNewswire (Europe) | PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, today publishes the Company's interim... ► Artikel lesen | |
| 31.07.25 | Pila Pharma AB: PILA PHARMA announces updated dates for last day of trading with paid subscribed units and first day of trading in new shares | 1.184 | GlobeNewswire (Europe) | PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") announces that the last day of trading in paid subscribed units (Sw. BTU) in connection with the Company's rights issue of units which the Board... ► Artikel lesen | |
| 26.06.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 26.06.2025 | 1.131 | Xetra Newsboard | Das Instrument 4LG CH0371153492 LANDIS+GYR GROUP AG SF 10 EQUITY wird cum Kapitalmassnahme gehandelt am 26.06.2025 und ex Kapitalmassnahme am 27.06.2025 The instrument 4LG CH0371153492 LANDIS+GYR GROUP... ► Artikel lesen | |
| 25.06.25 | Pila Pharma AB: Pila Pharma Publishes Prospectus In Connection With The Announced Rights Issue Of Units | 297 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH... ► Artikel lesen |
8 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 16,115 | -24,94 % | Summit Therapeutics falls after update on Akeso-partnered lung cancer trial | ||
| ERASCA | 10,000 | -6,10 % | Erasca, Inc.: Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L... ► Artikel lesen | |
| RELAY THERAPEUTICS | 12,720 | -1,85 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer | Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline development Compelling efficacy and tolerability data for zovegalisib triplet in median 3L patients 44% ORR in heavily pre-treated... ► Artikel lesen | |
| HEMAB THERAPEUTICS | 34,130 | 0,00 % | Hemab Therapeutics, Inc.: Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering | CAMBRIDGE, Mass. and COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine... ► Artikel lesen | |
| TANGO THERAPEUTICS | 20,960 | -3,05 % | Stifel raises Tango Therapeutics stock price target on drug combo potential | ||
| COGENT BIOSCIENCES | 36,630 | +2,35 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) | Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 323,50 | +1,46 % | Optimism Surrounds Praxis Precision Medicines (PRAX) Amid Potential FDA Approval for Ulixacaltamide | ||
| JANUX THERAPEUTICS | 14,340 | -0,21 % | Janux Therapeutics, Inc. - 8-K, Current Report | ||
| KINIKSA PHARMACEUTICALS | 55,23 | +2,70 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $930 - $945 million -- KPL-387... ► Artikel lesen | |
| CG ONCOLOGY | 66,21 | -0,79 % | CG Oncology Inc.: CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort CX Phase 2 first results of combination... ► Artikel lesen | |
| COMPASS THERAPEUTICS | 1,960 | +10,73 % | Morning Market Movers: Sagimet Biosciences, Compass Therapeutics, Oruka Therapeutics, Veradermics See Big Swings | SAN DIEGO (dpa-AFX) - At 8:00 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 42,110 | +1,59 % | Here is Why Structure Therapeutics (GPCR) is One of the Top Biotech Names to Look at | ||
| ZENAS BIOPHARMA | 19,360 | +0,21 % | Zenas BioPharma rises as CEO continues insider purchases | ||
| MINERALYS THERAPEUTICS | 29,300 | +9,94 % | Mineralys Therapeutics: TD Cowen startet Coverage mit Kaufempfehlung und sieht Blockbuster-Potenzial | ||
| ANNEXON | 5,750 | -2,04 % | Annexon Biosciences: Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones | ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA Tanruprubart MAA Filed in Europe with... ► Artikel lesen |
Das Unternehmen PILA PHARMA AB kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,79 % bei einem Aktienkurs von 0,128 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PILA PHARMA AB finden Sie auf Wallstreet Online.